By concurrently modulating oncogenic signaling and impairing anti-tumor immunity via CD8+ T cell dysfunction and immune exclusion, along with suppressing tumor-protective cellular program, PLXNA3 may play a dual role in driving colorectal cancer progression both through immune evasion and intrinsic cellular aggressiveness. This evidence concerns the gene CD8A and neoplasm.